[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"end-stage-kidney-disease-esrd\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:end-stage-kidney-disease-esrd":351},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,12,0,[8,54,81,110,131,153,182,218,245,278,302,326],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":30,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":46,"completionDateStruct":48,"leadSponsor":50,"locationsCount":53},"100644867",false,"NCT07676786","Euvolemia-Based Assessment of Pulmonary Hypertension in Stable Hemodialysis Patients","Prospective Observational Study on Predictors and Types of Pulmonary Hypertension in Euvolemic Patients With End-Stage Kidney Disease on Maintenance Hemodialysis","EU-PHASE-HD","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* End-stage kidney disease on maintenance HD for ≥ 3 months.\n* Stable clinical condition (no hospitalization in last 30 days).\n* Able and willing to comply with study protocol.\n* Provision of written informed consent\n\nExclusion Criteria:\n\n* Moderate\u002Fsevere left-sided valvular disease.\n* Active pulmonary or cardiac decompensation.\n* Persistent hypervolemia after completion of the volume assessment and correction phase\n* Inability to undergo echocardiography or bioimpedance assessment.\n* Acute infection or inflammatory condition at the time of enrollment.\n* Inadequate echocardiographic window preventing reliable assessment","ALL","18 Years",{"count":19,"type":20},30,"ESTIMATED","OBSERVATIONAL","Pulmonary hypertension (PH) is a frequent and clinically significant complication in patients with end-stage kidney disease (ESKD) undergoing maintenance hemodialysis (HD). However, PH assessment in this population is often confounded by volume overload, leading to potential overestimation and misclassification.\n\nThis prospective, multicenter observational study aims to evaluate the prevalence, phenotype, and predictors of PH in HD patients under standardized euvolemic conditions. A structured pretrial phase including volume assessment and correction will be performed prior to echocardiographic evaluation, which will be conducted after confirmation of euvolemia, post-hemodialysis or on the following day.\n\nIn participants with echocardiographic findings suggestive of PH, right heart catheterization may be performed when clinically indicated and after obtaining specific informed consent.\n\nThe study integrates clinical, biological, dialysis-related, and echocardiographic data to provide a comprehensive characterization of PH in a well-defined ESKD population.",[24,25,26,27,28,29],"Pulmonary Hypertension (PH)","End Stage Kidney Disease (ESRD)","Hemodialysis Patients","Volume Overload","Volume Assessment","Hemodialysis",[31,29,32,33,27,34,35,36,37,38,39,40],"Pulmonary Hypertension","End-Stage Kidney Disease","Euvolemia","Volume Status","Echocardiography","Bioimpedance Spectroscopy","Interdialytic Weight Gain","Vascular Access","Blood Pressure Variability","Lung Ultrasound","NOT_YET_RECRUITING","2026-06-24",{"date":44,"type":45},"2026-06-30","ACTUAL",{"date":47,"type":20},"2026-07-01",{"date":49,"type":20},"2027-03-30",{"name":51,"class":52},"Stefan Lujinschi","OTHER",2,{"id":55,"slug":4,"hasResults":10,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":59,"eligibilityCriteria":60,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":61,"targetDuration":4,"studyType":63,"phases":64,"briefSummary":66,"conditions":67,"keywords":68,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":53},"100609167","NCT07211035","Effect of the Amplifi™ Vein Dilation System on Outflow Vein Dilation and AV Fistula Maturation (AMPLIFI-1)","A Pivotal Study to Evaluate the Effect of the Amplifi™ Vein Dilation System on Outflow Vein Dilation and Arteriovenous Fistula Maturation","AMPLIFI-1","Inclusion Criteria:\n\n1. Age ≥ 18 years\n2. Indicated for wrist or distal forearm radiocephalic AVF creation based on Investigator's standard practice\n3. End-Stage Renal Disease (ESRD) receiving maintenance hemodialysis.\n4. Baseline cephalic vein diameter between \\>1.7 mm and \\\u003C3.2 mm at the proposed Study AVF creation site in the distal forearm, with a continuous distal segment or tributary suitable for Amplifi System Outflow Catheter placement, including:\n\n   * A forearm cephalic vein segment of ≥ 14 cm in length that provides an approximately 10 cm cannulation zone, free of detectable occlusions or stenosis, with collaterals.\n   * Central continuity of the forearm cephalic vein at the elbow demonstrated through one or any combination of the following pathways:\n\n     1. the upper arm cephalic vein,\n     2. the median cubital vein connecting to the upper arm basilic vein,\n     3. the perforator vein connecting to the deep venous system.\n   * Upper arm veins must show central continuity with no detectable occlusions.\n5. Palpable radial artery with a diameter of ≥ 2.0 mm at the site of proposed AVF creation without significant stenosis along the course\n6. Positive Allen's Test\n7. At least one patent internal jugular vein suitable for Amplifi Inflow Catheter insertion\n8. Subject has voluntarily signed written informed consent\n\nExclusion Criteria:\n\n1. Known allergy to Amplifi System components (polyurethane, nitinol), iodinated contrast agents, heparin, or apixaban\n2. Known or suspected active infection at the proposed time of Amplifi System placement\n3. Known bleeding diathesis, including from uncorrected coagulopathy\n4. Known thrombophilia, requiring treatment\n5. Hb \\\u003C7 gm\u002FdL\n6. Platelet level \\\u003C 100,000 \u002Fmm3\n7. Significant radial artery calcification\n8. Need for continued treatment with anti-platelet agents or other anticoagulants (other than apixaban) during the Amplifi System treatment period\n9. Known history of patent foramen ovale \\> 2 mm\n10. History of recent intracranial or gastrointestinal bleeding\n11. Documented recent central venous or right atrial thrombus\n12. Known presence or recent history of intracranial or gastrointestinal bleeding or presence of underlying conditions that would predispose to intracranial or internal bleeding. Documented recent central venous or right atrial thrombus\n13. History of recent ipsilateral central venous occlusion, stenosis \\> 50%, angioplasty, or stent placement\n14. Pregnancy, lactation, or plans to become pregnant during the Study\n15. Expected survival less than 12 months\n16. Unwillingness or inability to comply with procedures specified in the Protocol, or difficulty or inability to return for follow-up visits as specified by the Protocol\n17. Participation in any other investigational drug or medical device study that has not completed primary endpoint evaluation or clinically interferes with the endpoints from the Study, or planned future participation in such studies prior to the completion of the Study",{"count":62,"type":20},160,"INTERVENTIONAL",[65],"NA","The AMPLIFI-1 Study is a prospective, multicenter pivotal clinical trial designed to evaluate the safety and effectiveness of the Amplifi™ Vein Dilation System in patients requiring distal arteriovenous fistula (AVF) creation for hemodialysis. The study has two cohorts: a randomized controlled (RC) cohort of patients with suitable cephalic veins (≥2.5 mm) randomized 2:1 to Amplifi treatment plus AVF creation versus standard AVF creation alone, and a non-randomized small vein cohort (NRC) of patients with borderline veins (1.7 to \\\u003C2.5 mm) treated with Amplifi therapy followed by AVF creation.",[25],[69],"Pre-vein dilation for AVF access","RECRUITING","2026-06-22",{"date":73,"type":45},"2026-06-23",{"date":75,"type":45},"2026-05-12",{"date":77,"type":20},"2027-12-01",{"name":79,"class":80},"Amplifi Vascular, Inc.","INDUSTRY",{"id":82,"slug":4,"hasResults":10,"nctId":83,"briefTitle":84,"officialTitle":84,"acronym":85,"eligibilityCriteria":86,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":87,"targetDuration":4,"studyType":63,"phases":89,"briefSummary":91,"conditions":92,"keywords":96,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":102,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":53},"100594271","NCT07017270","Glucagon-like-peptide-1 Receptor Agonists in Patients Receiving Maintenance Dialysis","GUARD-1","Inclusion Criteria:\n\n1. Age ≥ 18\n2. Receiving chronic maintenance hemodialysis or peritoneal dialysis for ≥ 90 days\n3. confirmed DM2 based on medical history and current or prior receipt of an oral hypoglycemic agent and\u002For insulin.\n4. Ability to provided informed consent or through their substitute decision maker\n\nExclusion Criteria:\n\n1. Type 1 DM\n2. Use of a GLP-1-RA within 30 days prior to screening\n3. Personal or first-degree relative(s) with a history of type 2 multiple endocrine neoplasia syndrome or medullary thyroid cancer, or acute pancreatitis (within 180 days of study screening)\n4. Confirmed pregnancy, women of childbearing potential\n5. Known hypersensitivity to GLP-1-RA\n6. Expected to recover kidney function, stop hemodialysis, pursue palliative care, or transplantation within 6 months\n7. Enrolment in another clinical trial judged by the investigator to interact with the effect of GLP1-RA",{"count":88,"type":20},100,[90],"PHASE4","This study aims to determine if GLP1RA is safe and tolerable in maintenance dialysis population, adherence, and feasibility of a larger definitive cardiovascular outcome trial in this population. Participants will be randomized 1:1 to either weekly subcutaneous semaglutide versus usual care and followed for 26 weeks.",[93,94,95,25],"Kidney Disease, Chronic","Diabetes","Dialysis",[95,97,98,99,100,101],"Type 2 diabetes","semaglutide","end stage kidney disease","GLP1","GLP1RA",{"date":103,"type":45},"2026-06-26",{"date":105,"type":45},"2025-11-27",{"date":107,"type":20},"2027-09",{"name":109,"class":52},"Unity Health Toronto",{"id":111,"slug":4,"hasResults":10,"nctId":112,"briefTitle":113,"officialTitle":113,"acronym":114,"eligibilityCriteria":115,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":116,"targetDuration":4,"studyType":63,"phases":117,"briefSummary":118,"conditions":119,"keywords":4,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":130},"100619021","NCT07339202","Preoperative Hemodialysis Timing in Patients With End-Stage Kidney Disease: The POD-ESKD Pilot Trial","POD-ESKD","Inclusion Criteria:\n\n1. Patient is willing to comply with all study procedures for the duration of the study\n2. Patient has a diagnosis of ESKD\n3. Patient initiated hemodialysis at least 90 days prior to the planned surgical procedure\n4. Patient is treated with a stable hemodialysis schedule, defined as an average of 2.5- 3.5 hemodialysis sessions per week in the preceding 4 weeks prior to surgery\n5. Patient is scheduled to undergo nonemergent surgical procedures in the Stanford Health Care system. This includes (but is not limited to):\n\n   * Fistula or graft creation, revision, or removal\n   * Fistulogram\n   * Peritoneal dialysis catheter placement or revision\n   * Lower extremity angiogram (including femoral and iliac vessels)\n   * Lower extremity bypass (including femoral and iliac vessels)\n   * Lower extremity amputation\n   * Lower extremity endarterectomy (including femoral and iliac vessels) Of note, this list of procedures is not exhaustive and other procedures may be considered that meet inclusion criteria and no exclusion criteria, in consultation with the treatment teams involved.\n\nExclusion Criteria:\n\n1. Patient is pregnant\n2. Patient is a prisoner\n3. Patient is \\\u003C 18 years old\n4. The treating clinicians determine that the patient's clinical condition necessitate a specific approach to surgical scheduling or preoperative hemodialysis",{"count":19,"type":20},[65],"The goal of this clinical trial is to evaluate the feasibility of two different preoperative hemodialysis schedules for people with end-stage kidney disease (ESKD) who undergo surgical procedures. The main questions it aims to answer are:\n\nIs it feasible to randomize participants with ESKD undergoing nonemergent surgical procedures to same-day hemodialysis versus no same-day hemodialysis?\n\nIs it safe to randomize participants with ESKD undergoing nonemergent surgical procedures to same-day hemodialysis versus no same-day hemodialysis?\n\nResearchers will compare the two hemodialysis schedules to see if the scheduling and safety profiles are the same.\n\nParticipants will:\n\nAnswer questions about their health up to 4 weeks before and 4 weeks after the surgical procedure.\n\nReceive hemodialysis on the day of the surgical procedure or not, depending on the study treatment assignment.",[120,25,29],"Perioperative Management","2026-06-08",{"date":123,"type":45},"2026-06-11",{"date":125,"type":45},"2026-05-27",{"date":127,"type":20},"2027-10-15",{"name":129,"class":52},"Stanford University",1,{"id":132,"slug":4,"hasResults":10,"nctId":133,"briefTitle":134,"officialTitle":135,"acronym":4,"eligibilityCriteria":136,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":137,"targetDuration":4,"studyType":63,"phases":139,"briefSummary":140,"conditions":141,"keywords":142,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":144,"lastUpdatePostDateStruct":145,"startDateStruct":147,"completionDateStruct":149,"leadSponsor":151,"locationsCount":130},"100635671","NCT07555717","STARgraft (10401) Pilot","STARgraft Vascular Graft 10401 for Hemodialysis Access Pilot","Inclusion Criteria:\n\n1. Adult patients, 18 years or older.\n2. Patient has given informed consent to participate in the trial.\n3. Stated willingness to comply with all trial procedures and availability for the duration of the trial.\n4. Able to effectively communicate with trial personnel.\n5. Indicated patient population (end stage renal disease).\n6. Candidate for a new AV graft placed in the upper arm and judged to need dialysis within 2 months. Patient may have a failed access at a different anatomical location.\n7. Life expectancy judged to be at least 2 years with consideration of patient frailty.\n8. Axillary vein approximately 7 mm in diameter or greater.\n9. Brachial artery approximately 4 mm in diameter or greater.\n10. Acceptable cardiac risk level (cardiac output ≥ 3.5 l\u002Fmin, pulmonary artery pressure ≤ 50 mmHg, and ejection fraction ≥ 40%).\n11. Systolic blood pressure equal to or greater than 120 mmHg.\n12. Absence of central venous stenosis downstream from implant site confirmed with ultrasound and\u002For venogram.\n\nExclusion Criteria:\n\n1. Unable or unlikely to comply with trial protocol and\u002For follow-up.\n2. Pregnancy.\n3. Previous history of Peritoneal Dialysis treatment within the last 2 months\n4. Central venous catheter located on same side as intended implant location.\n5. Clinical morbid obesity (BMI \\> 40).\n6. Anatomical limitations, including issues discovered intraoperatively during vessel exposure.\n7. Immunodeficiency syndrome.\n8. History of hypercoagulation or bleeding disorders.\n9. Elevated platelet count \\> 1 million per microliter of blood.\n10. History of heparin-induced thrombocytopenia syndrome\n11. Medically confirmed stenosis or compromised valves in the veins downstream of the implant site.\n12. Inadequate arterial flow or pressure proximal to the implant site.\n13. Currently participating in another investigational drug or device trial which may clinically interfere with any endpoints of this trial.\n14. Fever greater than 38°C.\n15. Known allergic reaction to silicone, or untreatable allergy to imaging contrast materials.\n16. Confirmed or suspected bacterial, viral or parasitic infection within 8 weeks prior to graft implant, or ongoing symptoms.\n17. Uncontrolled or poorly controlled diabetes.\n18. History or evidence of severe cardiac disease.\n19. Any other condition which, in the judgment of the Investigator, would preclude adequate evaluation or impact patient safety or trial conduct.",{"count":138,"type":20},20,[65],"This study is a single site, prospective, single arm evaluation of the safety and effectiveness of the Healionics STARgraft (10401) hemodialysis access graft.\n\nThe study is enrolling patients with End Stage Renal Disease (ESRD) requiring hemodialysis via a prosthetic vascular graft. The study proposes to evaluate the performance of the investigational STARgraft (10401) compared to the ePTFE controls in a prior study (NCT03916731) and to published results, over a period of 6 months. Additional data out to 36 months post-implantation may be captured.",[25],[29,38,143],"Arterio-venous Grafts (AVG)","2026-04-21",{"date":146,"type":45},"2026-04-29",{"date":148,"type":45},"2026-01-29",{"date":150,"type":20},"2028-12",{"name":152,"class":80},"Healionics Corporation",{"id":154,"slug":4,"hasResults":10,"nctId":155,"briefTitle":156,"officialTitle":157,"acronym":158,"eligibilityCriteria":159,"healthyVolunteers":10,"sex":16,"minAge":160,"maxAge":4,"enrollmentInfo":161,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":163,"conditions":164,"keywords":167,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":172,"lastUpdatePostDateStruct":173,"startDateStruct":175,"completionDateStruct":177,"leadSponsor":179,"locationsCount":181},"100597551","NCT07059962","Sensor-based Congestion ALert for Events in Peritoneal Dialysis (SCALE-PD)","Sensor-based Congestion Alert for Events in Peritoneal Dialysis (SCALE-PD)","SCALE-PD","Inclusion Criteria:\n\n1. Age 21 years or older\n2. Able to speak and read English, or able to speak and read Spanish and has a caregiver or family member who speaks English and can provide assistance\n3. Able to stand on two bare feet unassisted\n4. Receiving automated peritoneal dialysis for the treatment of ESKD\n5. Followed on the Vantive Sharesource Remote Patient Management Platform\n\nExclusion Criteria:\n\n1. Undergoing or plan to undergo hemodialysis in the next 12 months\n2. Have a life expectancy of less than 12 months\n3. Are pregnant or plan to become pregnant during the next 12 months\n4. Weigh greater than 375 lbs\n5. Planned kidney transplant within the next 12 months\n6. Have an implanted neurostimulator system","21 Years",{"count":162,"type":20},125,"To explore the use of the Bodyport Cardiac Scale in predicting worsening of events due to fluid overload in patients with kidney disease on peritoneal dialysis.",[165,166,25],"Kidney Disease","Peritoneal Dialysis (PD)",[168,169,170,171],"kidney disease","peritoneal dialysis","fluid overload","heart failure","2026-03-17",{"date":174,"type":45},"2026-03-18",{"date":176,"type":45},"2025-09-09",{"date":178,"type":20},"2026-06",{"name":180,"class":80},"Bodyport Inc.",4,{"id":183,"slug":4,"hasResults":10,"nctId":184,"briefTitle":185,"officialTitle":186,"acronym":4,"eligibilityCriteria":187,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":188,"targetDuration":4,"studyType":63,"phases":189,"briefSummary":190,"conditions":191,"keywords":194,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":209,"lastUpdatePostDateStruct":210,"startDateStruct":212,"completionDateStruct":214,"leadSponsor":216,"locationsCount":130},"100605044","NCT07157397","Effect of a Plant-Focused Diet on Nutritional Status in Malnourished Peritoneal Dialysis Patients","Effect of Plant-Focused Diet on Nutritional Status of Malnourished Patients Undergoing Peritoneal Dialysis in a Selected Hospital Care Setting","Inclusion Criteria:\n\n* Adult outpatients (\\>18 years old), attending HTCM PD clinic visits\n* Have undergone peritoneal dialysis for at least 6 months\n* Have a serum albumin level \\\u003C40 g\u002FL\n* Have a BMI of \\\u003C 25 kg\u002Fm2\n* Have a malnutrition inflammation score (MIS) of mild, moderate or severe\n* Agreed to follow the dietary instructions based on the randomization assignment\n* Agreed to attend baseline visits and additional follow-up appointments at months 1, 3, and 6 post- randomization, either in person or via telehealth, and respond to monthly or more frequent phone calls\n\nExclusion Criteria:\n\n* Have been hospitalized for the past 3 months\n* Have ongoing infection\u002Fsepsis\n* Has undergone surgery in the past 6 months\n* Have high inflammatory diseases, malignancy, or cancer\n* Have dialysis adequacy of \\\u003C1.2 Kt\u002FV",{"count":88,"type":20},[65],"The goal of this clinical trial is to determine whether a plant-focused diet improves nutritional and health outcomes of malnourished adults undergoing peritoneal dialysis (PD). It will also learn about the safety of this diet in this population.\n\nThe main questions it aims to answer are:\n\n1. Does a plant-focused diet improve nutritional status compared to a standard kidney diet in PD patients?\n2. What changes occur in anthropometric, biochemical, and dietary measures over 6 months?\n\nResearchers will compare the plant-focused diet to a standard-of-care renal diet to see which is more effective in improving nutrition in PD patients.\n\nParticipants will:\n\n* Be randomly assigned to follow the plant-focused diet or the standard diet.\n* Be monitored for 6 months through in-person visits (aligned with their routine clinic appointments) and virtual check-ins via messages or calls.\n* Have their progress monitored for changes in outcomes such as nutrition, blood tests, kidney function, and quality of life.",[192,25,166,193],"End Stage Renal Disease (ESRD)","Malnourished",[195,196,197,198,199,200,201,202,203,204,205,206,207,208],"Peritoneal Dialysis","End Stage Renal Disease","End Stage Kidney Disease","Malnutrition","Plant-Focused Diet","Plant-Based Diet","Nutritonal Status","Dietary Counselling","Quality of Life","Physical Fitness","Inflammation","Appetite","Malaysia","Nutritional Intervention","2026-03-12",{"date":211,"type":45},"2026-03-16",{"date":213,"type":45},"2026-03-10",{"date":215,"type":20},"2027-03-31",{"name":217,"class":52},"National University of Malaysia",{"id":219,"slug":4,"hasResults":10,"nctId":220,"briefTitle":221,"officialTitle":222,"acronym":223,"eligibilityCriteria":224,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":225,"targetDuration":227,"studyType":21,"phases":4,"briefSummary":228,"conditions":229,"keywords":231,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":236,"lastUpdatePostDateStruct":237,"startDateStruct":239,"completionDateStruct":241,"leadSponsor":243,"locationsCount":130},"100627322","NCT07447128","Prospective Analysis of Arteriovenous Access (AVA) Use for Continuous Renal Replacement Therapy (CRRT)","Prospective Analysis of Arteriovenous Access Use in Continuous Renal Replacement Therapy, a Feasibility Project","CRRT","Inclusion Criteria:\n\n* Age 18 years or older\n* Diagnosis of End-Stage Kidney Disease (ESKD) receiving maintenance chronic hemodialysis\n* Admission to the Intensive Care Unit (ICU)\n* Presence of a functioning arteriovenous fistula (AVF) or arteriovenous graft (AVG)\n* Clinical indication for Continuous Renal Replacement Therapy (CRRT)\n* Score of ≥16 points on the study enrollment screening tool\n\nExclusion Criteria:\n\n* Age under 18 years\n* Arteriovenous access thrombectomy within 30 days prior to study enrollment\n* Documented prolonged bleeding from arteriovenous access within 30 days prior to study enrollment\n* Current dialysis via temporary or tunneled hemodialysis catheter\n* International Normalized Ratio (INR) \\> 3.0\n* Acute liver failure, defined as AST \\> 1000 U\u002FL and\u002For ALT \\> 1000 U\u002FL\n* Platelet count \\\u003C 50,000\u002FµL\n* Evidence of disseminated intravascular coagulation (DIC)\n* Pregnant patients\n* Patients actively attempting to become pregnant",{"count":226,"type":20},50,"30 Days","Arteriovenous fistula or graft are the ideal hemodialysis access. Nonetheless the most common access type used for Continuous Renal Replacement Therapy (CRRT) is either a temporary or permanent hemodialysis catheter. Recommendations for the use of catheters to deliver CRRT in end stage kidney disease (ESKD) patients are lacking on data and subjective to anecdotal experiences and expert consensus. The repetitive placement of catheters in ESKD patients have shown to increase the chances of central vascular stenosis which is one of the main risk factors that lead to access failure. Also, the repetitive use of dialysis catheters increases the risk for catheter associated infections. Dedicated studies demonstrating the safety and feasibility of using arteriovenous access (AVA) for CRRT are scarce. No screening criteria or algorithm exists to determine the adequate patient and clinical scenario to use AVA for CRRT.\n\nGoals of the study:\n\n1. To develop a standard operating procedure for the use of AVA in CRRT.\n2. Evaluate the safety and efficacy of using AVA for CRRT.",[230,25],"Continuous Renal Replacement Therapy (CRRT)",[232,233,223,234,235,197],"Arteriovenous access","Continuous Renal Replacement Therapy","AVA","ESKD","2026-02-27",{"date":238,"type":45},"2026-03-03",{"date":240,"type":20},"2026-03",{"date":242,"type":20},"2026-09",{"name":244,"class":52},"East Carolina University",{"id":246,"slug":4,"hasResults":10,"nctId":247,"briefTitle":248,"officialTitle":249,"acronym":250,"eligibilityCriteria":251,"healthyVolunteers":10,"sex":16,"minAge":252,"maxAge":4,"enrollmentInfo":253,"targetDuration":4,"studyType":63,"phases":254,"briefSummary":255,"conditions":256,"keywords":263,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":269,"lastUpdatePostDateStruct":270,"startDateStruct":272,"completionDateStruct":274,"leadSponsor":276,"locationsCount":4},"100625231","NCT07419945","Older Kidney Patient Optimisation Pretransplant","Optimising Access to and Outcomes From Transplantation in Older Potential Kidney Transplant Recipients: Pilot Feasibility Study on Kidney Transplant-specific Comprehensive Geriatric Assessment (KT-CGA)","OK-POP","Inclusion Criteria:\n\n* Adults aged 60 years or older\n* Attending Guy's and St Thomas' (GSTT) Nephrology services\n* Diagnosed with Chronic Kidney Disease (CKD) Stage 5\n\nEither:\n\n* Pre-dialysis, or\n* Receiving dialysis (in-centre haemodialysis, peritoneal dialysis, or home haemodialysis)\n* Referred to the kidney transplant surgical clinic for assessment of suitability for kidney transplantation (pre-transplant evaluation)\n\nExclusion Criteria:\n\n* Adults aged under 60 years\n* Patients currently attending the Nephrology Supportive Care service at GSTT","60 Years",{"count":226,"type":20},[65],"The goal of this clinical trial is to learn if a kidney transplant-specific comprehensive geriatric assessment (KT-CGA) can improve the way older adults are assessed for kidney transplantation. The main questions it aims to answer are:\n\nIs it feasible and acceptable to deliver a KT-CGA alongside routine transplant assessment in older adults with advanced kidney disease?\n\nWhat is the effect of KT-CGA on decision-making about transplant listing and on patient-reported outcomes such as quality of life and frailty?\n\nResearchers will compare participants who receive the KT-CGA plus usual care to those who receive usual care alone.\n\nParticipants will:\n\nContinue with their usual transplant assessment process\n\nIf randomised to the intervention group, also complete the KT-CGA (a structured set of questionnaires, short memory and function tests, and discussions about wellbeing and support needs, taking about 45-60 minutes)",[165,257,258,259,260,25,261,262],"Kidney Failure","Frailty","Cognitive Impairment","Multimorbidity","Kidney Transplant","Health Inequity",[264,265,266,267,99,268],"kidney transplant","frailty","multimorbidity","cognitive impairment","health inequality","2026-02-12",{"date":271,"type":45},"2026-02-19",{"date":273,"type":20},"2026-02-02",{"date":275,"type":20},"2028-02-02",{"name":277,"class":52},"Guy's and St Thomas' NHS Foundation Trust",{"id":279,"slug":4,"hasResults":10,"nctId":280,"briefTitle":281,"officialTitle":281,"acronym":4,"eligibilityCriteria":282,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":283,"targetDuration":4,"studyType":63,"phases":285,"briefSummary":286,"conditions":287,"keywords":289,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":293,"lastUpdatePostDateStruct":294,"startDateStruct":296,"completionDateStruct":298,"leadSponsor":300,"locationsCount":130},"100613809","NCT07271420","Blood Pressure Control With Thiazide Diuretics in Peritoneal Dialysis Patients","Inclusion Criteria:\n\n* Patients on chronic peritoneal dialysis, with uncontrolled hypertension (SBP \\>140 mmHg and\u002For DBP \\>90 mmHg)\n\nExclusion Criteria:\n\n* Patients with a life expectancy of less than 3 months, planned conversion to hemodialysis, or scheduled kidney transplantation within 3 months",{"count":284,"type":20},40,[90],"To evaluate the blood pressure lowering effects of thiazide diuretics in patients on peritoneal dialysis",[288,195,25],"Hypertension",[288,290,291,292],"Thiazides diuretics","End stage kidney disease","Peritoneal dialysis","2025-11-26",{"date":295,"type":45},"2025-12-09",{"date":297,"type":45},"2020-01-01",{"date":299,"type":20},"2027-06-30",{"name":301,"class":52},"Chinese University of Hong Kong",{"id":303,"slug":4,"hasResults":10,"nctId":304,"briefTitle":305,"officialTitle":306,"acronym":307,"eligibilityCriteria":308,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":309,"targetDuration":4,"studyType":63,"phases":311,"briefSummary":313,"conditions":314,"keywords":4,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":317,"lastUpdatePostDateStruct":318,"startDateStruct":320,"completionDateStruct":322,"leadSponsor":324,"locationsCount":181},"100394944","NCT04422652","Combination of Novel Therapies for CKD Comorbid Depression","Combination of Novel Therapies for CKD Comorbid Depression (CONCORD)","CONCORD","Inclusion Criteria:\n\n1. Male or female adults aged 18 years or greater. There will be no upper age limit.\n2. Presence of CKD stages 3b, 4 or 5, with an estimated glomerular filtration rate (GFR) of \\\u003C45 mL\u002Fmin\u002F1.73 m2 for a period of at least 3 months, as defined by the National Kidney Foundation and determined using the four-variable Modification of Diet for Renal Diseases Study formula.\n3. Presence of a current Major Depressive Disorder (MDD) based on MINI DSM IV-based criteria\n4. Quick Inventory of Depressive Symptomatology-Self-report (QIDS-SR) score of ≥11 at enrollment and ≥11 on QIDS-Clinician Rated (QIDS-C) at randomization.\n5. Able to understand and sign informed consent after the nature of the study has been fully explained\n6. Kidney transplant patients that are at least 6 month post-transplantation (3 months post-transplant, with at least another 3 months to confirm eGFR \\\u003C45)\n\nExclusion Criteria:\n\n1. Unable to understand or give informed consent.\n2. Unwilling or unable to participate in the protocol or comply with any of its components\n3. Significant hepatic dysfunction or liver enzyme abnormalities 3 times or greater than the upper limit of normal\n4. Terminal chronic obstructive pulmonary disease or cancer\n5. Presence of seizure disorder\n6. Current use of class I anti-arrhythmic medications (such as 1C propafenone and flecanide), pimozide, MAO inhibitors, reserpine, guanethidine, cimetidine, or methyldopa; tri-cyclic anti-depressants, neuroleptics, or anti-convulsants\n7. Use of serotonergic drugs or supplements such as triptans, tramadol, linezolid, tryptophan, and St. John's Wort.\n8. Use of medications known to cause QT prolongation on EKG\n9. Ongoing use of antidepressant medications for depression treatment\n10. Past treatment failure on bupropion\n11. Initiation of depression-focused psychotherapy in the 3 months prior to study entry\n12. Active alcohol or substance abuse or dependence that requires acute detoxification at study entry\n13. Present or past psychosis or Bipolar I or II disorder\n14. Dementia or a Mini-Mental State Examination score \\\u003C23\n15. Active suicidal intent\n16. Pregnancy, lactation, or women of childbearing potential not willing to use adequate contraception",{"count":310,"type":20},201,[312],"PHASE2","The overall goal of the study is to determine if treatment of a Major Depressive Disorder (MDD) improves the outcomes of patients with chronic kidney disease (CKD). We showed that MDD is present in 25% of CKD patients and independently associated with progression to End-Stage Kidney Disease, hospitalization, and death. Depression is also associated with lower quality of life (QOL), fatigue, poor sleep, and non-adherence to diet and medications. However, evidence for efficacy and tolerability of commonly-used antidepressant medications or nonpharmacologic treatments are limited in CKD patients. Our group was the first to conduct a double-blind randomized controlled trial for MDD treatment in 201 patients with non-dialysis CKD, and showed that sertraline, a commonly used selective serotonin reuptake inhibitor (SSRI), was no more efficacious than placebo for improving depressive symptoms. It becomes imperative to test novel strategies to treat MDD in CKD. We propose to compare with a control group, the efficacy and tolerability of two novel treatment strategies - (1) Behavioral Activation Teletherapy (BAT) for 16 weeks, with the addition of bupropion, a non-SSRI antidepressant, at 8 weeks for patients whose depression has not remitted (non-remitters); and (2) bupropion for 16 weeks, with the addition of BAT at 8 weeks for non-remitters. In Aim 1, we will investigate the efficacy and tolerability of these 2 strategies vs. control for improvement in a primary endpoint of depressive symptoms in 201 patients (67 per group) with CKD stages 3b-5 and MDD at 2 sites, randomized 1:1:1 to either strategy or a control group of Clinical Management plus placebo. We hypothesize that either approach vs. control will result in a minimal clinically important difference of 2 points improvement in depressive symptoms, as ascertained blindly by the Quick Inventory of Depressive Symptomatology. In Aim 2 we will investigate the efficacy and tolerability of 8 weeks of (1) single-blind BAT plus placebo or (2) double-blind bupropion plus Clinical Management vs. control for improvement in depressive symptoms. In Aim 3, we will compare the efficacy of these 2 treatments strategies vs. control for improvement in CKD patient-centered outcomes including a. adherence to medications and healthcare visits; b. fatigue; c. sleep; and d. overall functioning. A clinical trial is urgently needed to address the evidence gap that exists for MDD treatment in CKD patients.",[315,316,25],"Chronic Kidney Diseases","Major Depressive Disorder","2025-11-21",{"date":319,"type":45},"2025-11-28",{"date":321,"type":45},"2020-09-24",{"date":323,"type":20},"2027-04-01",{"name":325,"class":52},"Stony Brook University",{"id":327,"slug":4,"hasResults":10,"nctId":328,"briefTitle":329,"officialTitle":329,"acronym":4,"eligibilityCriteria":330,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":331,"targetDuration":4,"studyType":63,"phases":333,"briefSummary":334,"conditions":335,"keywords":338,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":342,"lastUpdatePostDateStruct":343,"startDateStruct":345,"completionDateStruct":347,"leadSponsor":349,"locationsCount":130},"100592166","NCT06989892","Comparing Super High-flux and High-flux Dialyzer Performance Among Hemodialysis Patient With Sepsis : a Randomized Control Trial","Inclusion Criteria:\n\n* ESKD patients who have sepsis condition with high interleukin-6 (IL-6 \\> 50 pg\u002Fml)\n\nExclusion Criteria:\n\n* Patients who needed dialysis with continuous kidney replacement therapy, vulnerable patient, include pregnant woman, patient who expected to pass away within the 24 hours.\n* Patients who have the history of allergic dialyzer reaction to dialyzer which used in this trial.",{"count":332,"type":20},202,[65],"Comparing the efficacy of superhigh-flux dialyzer with high-flux dialyzer in ESKD patient who have sepsis to improve mortality and sepsis outcome, an open label randomized control trial.",[336,25,337],"The Efficacy and Safety for Super High-flux Dialyzer in Case of Sepsis in ESKD","Sepsis",[339,340,99,341],"Superhighflux","hemodialysis","sepsis","2025-05-19",{"date":344,"type":45},"2025-05-25",{"date":346,"type":45},"2024-07-25",{"date":348,"type":20},"2026-10-01",{"name":350,"class":52},"Navamindradhiraj University",""]